Cardiol Therapeutics Inc. (FRA:CT9)

Germany flag Germany · Delayed Price · Currency is EUR
0.8680
+0.0280 (3.33%)
Last updated: Dec 1, 2025, 8:10 AM CET
-39.13%
Market Cap92.15M
Revenue (ttm)n/a
Net Income (ttm)-21.28M
Shares Outn/a
EPS (ttm)-0.26
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume317
Open0.8680
Previous Close0.8400
Day's Range0.8680 - 0.8680
52-Week Range0.6000 - 1.5840
Betan/a
RSI48.62
Earnings DateNov 19, 2025

About Cardiol Therapeutics

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the developing of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical develop... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2017
Employees 18
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol CT9
Full Company Profile

Financial Performance

Financial numbers in CAD Financial Statements

News

There is no news available yet.